Project Details
Description
Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO study)
| Status | Active |
|---|---|
| Effective start/end date | 12/1/17 → 3/31/25 |
Funding
- BIG TEN CANCER RESEARCH CONSORTIUM
- BRISTOL-MYERS SQUIBB COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.